| Project/Area Number |
10671603
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | KUMAMOTO UNIVERSITY |
|---|
Principal Investigator |
EURA Masao Department of Otolaryngology, KUMAMOTO UNIVERSITY, Assistant Professor, 医学部・附属病院, 講師 (60193984)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
江浦 正郎 熊本大学, 医学部・附属病院, 講師 (60193984)
|
|---|
| Project Period (FY) |
1998 – 1999
|
| Project Status |
Completed (Fiscal Year 1999)
|
| Budget Amount *help |
¥3,200,000 (Direct Cost: ¥3,200,000)
Fiscal Year 1999: ¥1,400,000 (Direct Cost: ¥1,400,000)
Fiscal Year 1998: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
|---|
| Keywords | head-and-neck cancer / tumor antigens / CTL / HLA-A24 molecules / MAGE-3 gene / p53 tumor suppressor gene / 癌細胞傷害性T細胞(CTL) / 頭剄部癌 / 癌関連抗原 / HLA-A24 |
|---|
| Research Abstract |
Tumor specific antigen MAGE-3 is expressed in approximately half of squamous cell carcinoma of the head and neck (SCCHN). We have demonstrated that MAGE-3-derived peptide M-3p97 (TFPDLESEF), with high binding capacity to HLA-A24 molecules, elicited the peptide specific cytotoxic T lymphocytes using peptide-pulsed autologous dendritic cells. Another group has also succeeded in generating CTLs specific for a different MAGE-3-derived epitope. We, therefore, tried to address a question that which peptide is immunodominat in generating MAGE-3-specific and HLA-A24-restricted CTL. The results suggest that the two peptides have equal potential in inducing MAGE-3-specific and HLA-A24-restricted CTLs and are equally available for specific immunotherapy against MAGE-3+/HLA-A24+ cancer cells.
Mutation of the p53 tumor suppressor gene is one of the most common genetic alterations in SCCHN, occurring in approximately 50% of SCCHN. We have also succeeded in generating CTLs specifc for a p53-derived peptide p53125-134.(TYSPALNKMF). Moreover, these CTLs lysed HLA-A24+ squamous cell carcinoma of the head and neck cell lines with p53 protein accumulation.
Taken together, these results suggest the therapeutic potential of MAGE-3- and/or p53-based cancer vaccines.
|
